Small-molecule drugs development for Alzheimer’s disease

Published on November 1, 2022

Imagine a complicated mystery with two main suspects, beta-amyloid cascade and hyperphosphorylated tau protein, who could be responsible for causing irreversible damage to the brain. But wait, there’s more! Other potential culprits include oxidative stress, deficiency of central cholinergic neurotransmitters, mitochondrial dysfunction, and inflammation. This review gathers all the small-molecule drugs designed to target these troublemakers, aiming to shed light on Alzheimer’s disease (AD) and open doors for new, effective treatments. The world needs heroes to unravel the mysteries behind AD and find new ways to conquer its challenges! So hop on board and explore the latest research in this exciting field.

Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative brain disorder with no effective therapeutic drugs currently. The complicated pathophysiology of AD is not well understood, although beta-amyloid (Aβ) cascade and hyperphosphorylated tau protein were regarded as the two main causes of AD. Other mechanisms, such as oxidative stress, deficiency of central cholinergic neurotransmitters, mitochondrial dysfunction, and inflammation, were also proposed and studied as targets in AD. This review aims to summarize the small-molecule drugs that were developed based on the pathogenesis and gives a deeper understanding of the AD. We hope that it could help scientists find new and better treatments to gradually conquer the problems related to AD in future.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>